Price alert —
Sign in to get a one-time email the moment IRON crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · IRON
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | $-0.1B | $-0.1B | $-0.1B | — | — |
| 2025-12-31 | — | $-0.1B | $-0.1B | $-0.0B | — | — |
| 2025-09-30 | — | $-0.1B | $-0.1B | $-0.0B | — | — |
| 2025-06-30 | — | $-0.1B | $-0.1B | $-0.0B | — | — |
| 2025-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare IRON vs peers
Line IRON up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with IRON
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 14 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-05 | -1.65 | -1.73 | +4.4% | +1.6% |
| 2026-02-26 | -1.62 | -1.70 | +4.9% | -1.9% |
| 2025-11-06 | -1.77 | -1.46 | -20.9% | -3.6% |
| 2025-08-07 | -1.58 | -1.14 | -38.6% | +1.7% |
| 2025-05-07 | -1.02 | -1.07 | +5.0% | +1.7% |
| 2025-02-27 | -0.98 | -1.10 | +11.2% | +3.1% |
| 2024-11-12 | -0.89 | -1.05 | +15.6% | -0.3% |
| 2024-08-08 | -1.03 | -1.10 | +6.7% | +0.6% |
| 2024-05-09 | -1.09 | -0.99 | -10.3% | -1.3% |
| 2024-03-21 | -0.97 | -0.77 | -25.8% | -1.3% |
| 2023-11-09 | -0.58 | -0.80 | +27.5% | +0.3% |
| 2023-08-11 | -0.74 | -0.89 | +16.9% | -1.4% |
| 2023-05-15 | -1.20 | -0.66 | -80.5% | +4.3% |
| 2023-03-31 | -40.91 | -0.84 | -4770.2% | +3.5% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| IRON ★ | $3B | — | -10.0 | — | -8.4 | 4.2 | — | — | — | -4.17% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 54.74%
| Holder | Shares | % out |
|---|---|---|
| FMR, LLC | 5,586,894 | 14.63% |
| RA Capital Management, L.P. | 2,450,221 | 6.41% |
| Blackrock Inc. | 2,273,831 | 5.95% |
| Wellington Management Group, LLP | 1,735,376 | 4.54% |
| State Street Corporation | 1,698,244 | 4.45% |
| Price (T.Rowe) Associates Inc | 1,549,350 | 4.06% |
| Atlas Venture Life Science Advisors, | 1,513,875 | 3.96% |
| Vanguard Capital Management LLC | 1,375,430 | 3.60% |
| JPMORGAN CHASE & CO | 1,371,480 | 3.59% |
| Frazier Life Sciences Management, L. | 1,354,852 | 3.55% |
Insider activity · 90d
0 buys / 6 sells · ratio 0.0 · Finnhub
- Quisel John D M 124,586
- Quisel John D M 15,791
- Quisel John D SELL 226,064 @ $76.05
- Quisel John D SELL 232,464 @ $74.95
- Quisel John D SELL 249,360 @ $74.27
- Quisel John D M 259,064 @ $13.50
- Quisel John D M 251,648 @ $9.86
- Yu Jonathan Yen-Wen M 23,747
- Yu Jonathan Yen-Wen SELL 54,324 @ $82.50
- Yu Jonathan Yen-Wen M 54,424 @ $13.50
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-14 | 4 | view · |
| 4 | 2026-07-09 | 4 | view · |
| 4 | 2026-06-30 | 4 | view · |
| 4 | 2026-06-30 | 4 | view · |
| 8-K | 2026-06-30 | 8-K | view · |
| 4 | 2026-06-24 | 4 | view · |
| 8-K | 2026-06-24 | 8-K | view · |
| 4 | 2026-06-23 | 4 | view · |
| 4 | 2026-06-23 | 4 | view · |
| 4 | 2026-06-23 | 4 | view · |
| 4 | 2026-06-23 | 4 | view · |
| 4 | 2026-06-23 | 4 | view · |
| 4 | 2026-06-23 | 4 | view · |
| 4 | 2026-06-23 | 4 | view · |
| 4 | 2026-06-23 | 4 | view · |
| 4 | 2026-06-23 | 4 | view · |
| 4 | 2026-06-18 | 4 | view · |
| 10-Q | 2026-05-05 | 10-Q | view · |
| 8-K | 2026-05-05 | 8-K | view · |
| DEF 14A | 2026-04-28 | DEF 14A | view · |
| 4 | 2026-04-15 | 4 | view · |
| 4 | 2026-04-15 | 4 | view · |
| 4 | 2026-03-04 | 4 | view · |
| 4 | 2026-02-27 | 4 | view · |
| 8-K | 2026-02-27 | 8-K | view · |
| 10-K | 2026-02-26 | 10-K | view · |
| 8-K | 2026-02-26 | 8-K | view · |
| 4 | 2026-02-19 | 4 | view · |
| 4 | 2026-02-17 | 4 | view · |
| 4 | 2026-02-17 | 4 | view · |
| 4 | 2026-02-17 | 4 | view · |
| 4 | 2026-02-17 | 4 | view · |
| 4 | 2026-02-17 | 4 | view · |
| 8-K | 2026-02-17 | 8-K | view · |
| 8-K | 2026-02-13 | 8-K | view · |
| 4 | 2026-02-11 | 4 | view · |
| 4 | 2026-02-11 | 4 | view · |
| 4 | 2026-02-11 | 4 | view · |
| 4 | 2026-02-11 | 4 | view · |
| 4 | 2026-02-11 | 4 | view · |
| 4 | 2026-02-11 | 4 | view · |
| 4 | 2026-01-21 | 4 | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 4 | 2026-01-05 | 4 | view · |
| 4 | 2025-12-29 | 4 | view · |
| 4 | 2025-12-19 | 4 | view · |
| 4 | 2025-12-18 | Insider transaction (Form 4) | view · |
| 4 | 2025-12-16 | OWNERSHIP DOCUMENT | view · |
| 4 | 2025-12-16 | 4 | view · |
| 4 | 2025-12-15 | 4 | view · |
| 8-K | 2025-12-08 | 8-K | view · |
| 4 | 2025-11-13 | 4 | view · |
| 10-Q | 2025-11-06 | 10-Q | view · |
| 8-K | 2025-11-06 | 8-K | view · |
| 4 | 2025-10-24 | 4 | view · |
| 8-K | 2025-10-22 | 8-K | view · |
| 8-K | 2025-10-20 | 8-K | view · |
| 4 | 2025-10-17 | Insider transaction (Form 4) | view · |
| 8-K | 2025-10-17 | 8-K | view · |
| 4 | 2025-10-09 | Insider transaction (Form 4) | view · |
About IRON
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Options picks · IRON
ITM + OTM ideas from the latest scanLoading…
Congress trades · IRON
STOCK Act disclosuresLoading…
SEC filings & insiders · IRON
EDGAR · liveLoading…
Holders · IRON
Institutions & insider activityLoading…